Treatments available for more advanced prostate cancer include hormone therapy with gonadotropin‐releasing hormone (GnRH) agonists, including goserelin, leuprorelin and triptorelin, (±anti‐androgens), in combination with radiation therapy or as monotherapy, depending on the tumor stage. This evidence concerns the gene GNRH1 and prostate cancer.